Tag Archives: QIAGEN N.V.

QIAGEN announces new milestones for its QuantiFERON tuberculosis test

(PRESS RELEASE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a German provider of Sample to Insights solutions that enable customers to unlock insights from the building … Read the full press release

QIAGEN N.V. forms joint venture with Maccura Biotechnology Co., Ltd., a leading in vitro diagnostics (IVD) company in China

Partnership with a leading Chinese IVD company with goal to accelerate penetration of the world’s first complete Sample to Insight NGS solution in rapidly growing Chinese market Hilden, Germany, and Chengdu, China, 08-May-2017 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt … Read the full press release

QIAGEN N.V. and Hamilton Robotics to serve the growing need for DNA fingerprinting of samples for human identity databases

Partnering with Hamilton Robotics to deliver automated workflows for DNA fingerprinting  Hilden, Germany, and Germantown, Maryland, 13-Oct-2016 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of automated high-throughput solutions, developed in partnership with Hamilton … Read the full press release

QIAGEN N.V. to submit conditional voluntary takeover offer to purchase all shares in Exiqon

Transaction will expand leadership position in RNA technologies Venlo, The Netherlands, 01-Apr-2016 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it has decided to submit a conditional voluntary takeover offer to the shareholders of … Read the full press release

QIAGEN N.V. starts commercialization activities for its GeneReader NGS System

First truly end-to-end solution brings next-generation sequencing within reach for any lab Austin, Texas, and Hilden, Germany, 6-11-2015 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the start of commercialization activities for its GeneReader NGS System, … Read the full press release

QIAGEN N.V. to increase global access to advanced cervical cancer screening technologies for women most in need

Global launch of CE marked careHPV and new CE marked self-collection claim for HPV sampling device help to provide HPV screening for women most in need HILDEN, Germany, 17-9-2015 — /EuropaWire/ — QIAGEN N.V. today announced its latest initiative to increase … Read the full press release

QIAGEN N.V. announces new capabilities for its Ingenuity® Variant Analysis™ and CLC Cancer Research Workbench solution

Translational research in cancer and other diseases will benefit from new capabilities being presented at the American Society of Human Genetics annual meeting Volume of 250,000-plus DNA samples linked to Ingenuity® Knowledge Base greatly exceeds any comparable database – providing … Read the full press release